Demetrix uses synthetic biology to engineer yeast strains to produce cannabinoids and nutraceuticals. The company’s co-founder, Dr. Jay Keasling, is a pioneer in biotechnology and microbial engineering at UC Berkeley. Through an exclusive licensing agreement on Keasling’ research from Berkeley, Demetrix plans to isolate and develop new cannabinoids to start screening for potential utility.